Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depiwhite Serum vs Hydroquinone in Melasma
NCT07071363Recruiting
- Sponsor
- Laboratoire Dermatologique ACM
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Depiwhite in melasma (2 arms), sponsored by Laboratoire Dermatologique ACM. Primary endpoint: Modified Melasma Area and Severity Index at Day 84. Started Jun 2025; status: recruiting.
02
Drugs
Depiwhite
03
Conditions
melasma
Beyond the preview
Go deeper on NCT07071363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071363.